Related Experiment Videos

Estramustine inhibits monocyte phagocytosis

L Bjermer1, E von Schoultz, B Norberg

  • 1Department of Oncology, University of Umeå, Sweden.

The Prostate
|January 1, 1988
PubMed

Insights

Estramustine phosphate (EMP) significantly impairs human monocyte phagocytosis of yeast cells in vitro. This immune cell function inhibition, observed at clinical concentrations, suggests potential pathophysiological implications for cancer patients undergoing treatment.

Area of Science:

  • Immunology
  • Pharmacology
  • Cell Biology

Background:

  • Estramustine phosphate (EMP) is utilized in advanced prostatic carcinoma treatment.
  • Understanding EMP's impact on immune cell function is crucial for patient management.
  • Phagocytosis is a key immune process involving engulfment and adherence.

Purpose of the Study:

  • To investigate the in vitro effect of Estramustine phosphate (EMP) on human monocyte phagocytosis.
  • To differentiate the impact of EMP on yeast cell engulfment versus adherence.
  • To assess the role of EMP metabolites in phagocytosis.

Main Methods:

  • Utilized a modified Hed's technique for in vitro phagocytosis assays.
  • Employed fluorescein isothiocyanate (FITC)-labeled yeast cells for monitoring.
  • Measured human monocyte interaction with yeast cells, distinguishing engulfment and adherence.

Main Results:

  • Estramustine phosphate (EMP) at clinical concentrations (20-40 µg/ml) significantly inhibited yeast cell engulfment by monocytes.
  • Cell adherence was less affected compared to the engulfment phase.
  • EMP metabolites, estradiol and normustine, did not impact yeast cell engulfment.

Conclusions:

  • Estramustine phosphate (EMP) directly impairs the phagocytic engulfment process, potentially via microtubule interaction.
  • The observed inhibition of phagocytosis by EMP may have pathophysiological significance in immunocompromised cancer patients.
  • Effects of EMP on phagocytosis were fully reversible.

Related Concept Videos